What's new? Log in Free sign up

Sonoma Pharmaceuticals (SNOA)

Company Profile

Company profile

Ticker

SNOA

Exchange

Website

www.sonomapharma.com

CEO

Ms. Amy M. Trombly

Incorporated

Location

Fiscal year end

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Ares Capital • Becton, Dickinson and • Stryker • Boston Scientific • Solventum • Baxter International • Teleflex • Hercules Capital • ResMed ...

Former names

Oculus Innovative Sciences, Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

680423298

SNOA stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Quarterly report

5 Feb 25

Entry into a Material Definitive Agreement

Departure of Directors or Certain Officers

Registration of securities for employees

Termination of a Material Definitive Agreement

Quarterly report

7 Nov 24

Sonoma Pharmaceuticals, Inc. Investor Presentation October 2024

Prospectus supplement for primary offering

Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

JOHN MCLAUGHLIN

Amy Moss Trombly

Philippe Weigerstorfer

JEROME J DVONCH

Poggetto John Dal

Notice of proposed sale of securities

Notice of proposed sale of securities (amended)

Notice of proposed sale of securities (amended)

Financial summary

Financial statements Chart SNOA financial data

Quarter (USD)	Dec 24	Sep 24	Jun 24	Mar 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Mar 24	Mar 23	Mar 22	Mar 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	5.24 mm	5.24 mm	5.24 mm	5.24 mm	5.24 mm	5.24 mm
Cash burn (monthly)	(no burn)	(no burn)	343.67 k	371.92 k	(no burn)	(no burn)
Cash used (since last report)	n/a	n/a	709.42 k	767.74 k	n/a	n/a
Cash remaining	n/a	n/a	4.53 mm	4.47 mm	n/a	n/a
Runway (months of cash)	n/a	n/a	13.2	12.0	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

SNOA institutional ownership history Ownership history

37.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	11	20	-45.0%
Opened positions	4	19	-78.9%
Closed positions	13	0	NEW
Increased positions	1	0	NEW
Reduced positions	5	0	NEW

13F shares	Current	Prev Q	Change
Total value	91.65 mm	94.18 mm	-2.7%
Total shares	599.19 k	1.01 mm	-40.5%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Montreux Equity Partners V	571.43 k	$6.43 mm	0.0%
UBS UBS	12.73 k	$39.08 mm	+6.8%
Ground Swell Capital	10.40 k	$31.93 mm	NEW
Tower Research Capital	4.14 k	$12.71 mm	-49.9%
C Citigroup	180.00	$553.00 k	NEW
JPM JPMorgan Chase & Co.	138.00	$424.00 k	NEW
BlackRock	113.00	$347.00 k	NEW
Advisor	27.00	$82.00 k	-86.5%
USB U.S. Bancorp	25.00	$77.00 k	-95.0%
Allworth Financial	3.00	$10.00 k	-95.4%

Largest transactions	Shares	Bought/sold	Change
Citadel Advisors	0.00	-195.16 k	EXIT
Geode Capital Management	0.00	-86.64 k	EXIT
Jane Street	0.00	-45.30 k	EXIT
STT State Street	0.00	-24.32 k	EXIT
HRT Financial	0.00	-21.52 k	EXIT
XTX Topco	0.00	-19.83 k	EXIT
Two Sigma Securities	0.00	-15.33 k	EXIT
Ground Swell Capital	10.40 k	+10.40 k	NEW
Tower Research Capital	4.14 k	-4.13 k	-49.9%
Qube Research & Technologies	0.00	-3.40 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SNOA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 Jan 25	Jay E Birnbaum	Stock option Common Stock	Grant	Acquire A	No	No	2.68	7,500	20.10 k	10,029
2 Jan 25	Jerome J Dvonch	RSU Common Stock	Grant	Acquire A	No	No	0	10,000	0.00	15,891
2 Jan 25	John Mclaughlin	Stock option Common Stock	Grant	Acquire A	No	No	2.68	7,500	20.10 k	10,044
2 Jan 25	Bruce Thornton	RSU Common Stock	Grant	Acquire A	No	No	0	10,000	0.00	18,691
2 Jan 25	Amy Moss Trombly	RSU Common Stock	Grant	Acquire A	No	No	0	10,000	0.00	18,685

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Sonoma Pharmaceuticals Q3 2025 GAAP EPS $(0.63) Beats $(0.69) Estimate, Sales $3.564 Miss $4.060M Estimate

Sonoma Pharmaceuticals (NASDAQ:SNOA) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.69) by 8.7 percent. This is a 60.63 percent increase over losses of $(1.60) per share

12 Health Care Stocks Moving In Friday's Pre-Market Session

Sonoma Pharmaceuticals Transitions First Products To New EU MDR Requirements For 4 Of Its Products In Europe

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications,

Press releases

From Benzinga Pro

Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando

BOULDER, CO / ACCESS Newswire / February 25, 2025 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results

Revenues increased 14% for the quarter compared to prior year and 13% year-to-datePositive cash flow from operations for the quarter with $5.2 million of cash at December 31, 2024Year-to-date net loss decline of $1.1

Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices

BOULDER, CO / ACCESSWIRE / December 5, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.